| Schedule of Segment Financial Information |
Schedule
of Segment Financial Information
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| |
|
Three Months Ended September 30,
|
|
|
Nine Months Ended September 30,
|
|
| |
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
| Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Clinical |
|
$ |
- |
|
|
$ |
1,920,092 |
|
|
$ |
705,645 |
|
|
$ |
4,359,819 |
|
| Chemistry, manufacturing and controls |
|
|
36,274 |
|
|
|
127,781 |
|
|
|
320,104 |
|
|
|
346,273 |
|
| Personnel related |
|
|
468,113 |
|
|
|
353,486 |
|
|
|
1,377,614 |
|
|
|
1,305,109 |
|
| Total research and development |
|
|
504,387 |
|
|
|
2,401,359 |
|
|
|
2,403,363 |
|
|
|
6,011,201 |
|
| Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Public company compliance |
|
|
475,503 |
|
|
|
562,777 |
|
|
|
1,991,676 |
|
|
|
2,147,927 |
|
| Marketing |
|
|
472,940 |
|
|
|
- |
|
|
|
472,940 |
|
|
|
- |
|
| Personnel related |
|
|
307,841 |
|
|
|
261,517 |
|
|
|
1,005,226 |
|
|
|
1,153,826 |
|
| Total selling, general and administrative |
|
|
1,256,284 |
|
|
|
824,294 |
|
|
|
3,469,842 |
|
|
|
3,301,753 |
|
| Interest income |
|
|
68,682 |
|
|
|
52,497 |
|
|
|
176,536 |
|
|
|
176,431 |
|
| Net loss |
|
$ |
(1,691,989 |
) |
|
$ |
(3,173,156 |
) |
|
$ |
(5,696,669 |
) |
|
$ |
(9,136,523 |
) |
|